Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06791122 · ClinicalTrials.gov registry record · NA
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
A NA study of Schizophrenia, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- NA
- Development phase
- 262
- Enrollment target
- 20
- Study locations
NCT06791122 is a NA study of Schizophrenia that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 262 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06791122, a NA study of Schizophrenia, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 262 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They may continue using it for another 16 weeks. During the study, participants continue with their normal treatment for schizophrenia. Participants are in the study for about a year. During this time, they visit the study site every 2 months. During this study, doctors regularly check participants' schizophrenia symptoms and overall quality of life. Researchers may also compare the healthcare data of study participants with a similar group of people with schizophrenia who are not part of the study. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DEVICE Digital therapeutic (CT-155)
Study Locations (20)
California
- Sun Valley Behavioral Med Center - Imperial
- University of California San Diego - La Jolla
- North Country Clinical Research Inc - Oceanside
- ATP Clinical Research, Inc. - Orange
- NRC Research Institute - Orange
- Stanford University Medical Center - Stanford
- Collaborative Neuroscience Research - Torrance
Florida
- Galiz Research - Hialeah
- New Life Medical Research Center, Inc. - Hialeah
- University of Miami - Miami
- Global Life Research Network - Miami
- Interventional Psychiatry of Tampa Bay - Tampa
- Health Synergy Clinical Research, LLC - West Palm Beach
Maryland
- Sheppard Pratt Physicians's Practice Association, Inc. - Baltimore
- Center for Behavioral Health, LLC - Gaithersburg
Massachusetts
- Boston Neurobehavioral Associates - Brookline
- University of Massachusetts - Worcester - Worcester
Connecticut
- CT Clinical Research - Cromwell
Georgia
- Emory University - Atlanta
Michigan
- Western Michigan University - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2026-08-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06791122
The ClinicalTrials.gov registry entry for NCT06791122 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (20% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Digital therapeutic (CT-155) is the first listed.
NCT06791122 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06791122 about?
NCT06791122 is a clinical study titled "A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia". This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new infor...
What is the current status of trial NCT06791122?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 262 participants. The study started on 2025-01-23. Estimated completion is 2026-08-26.
What conditions does trial NCT06791122 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT06791122?
The interventions under investigation include: Digital therapeutic (CT-155) (DEVICE).
Who is sponsoring clinical trial NCT06791122?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06791122 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.